PAVmed's Lucid Diagnostics Advances Cancer Prevention at MedTech Forum 2025

Lucid Diagnostics Expands Reach in Cancer Prevention at Upcoming MedTech Forum

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., announces its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, scheduled for November 20, 2025, in New York City. This event represents a significant opportunity for Lucid to engage with investors and industry stakeholders, particularly as it focuses on its innovative cancer prevention strategies. The Chief Financial Officer, Dennis McGrath, will be available for one-on-one meetings, providing a platform for in-depth discussions on the company's future direction and growth potential.

Lucid Diagnostics specializes in addressing the critical health challenges associated with gastroesophageal reflux disease (GERD), which is known to increase the risk of esophageal precancer and cancer. At the forefront of its offerings is the EsoGuard® Esophageal DNA Test, recognized as the first commercially available tool designed to facilitate early detection of esophageal precancer in at-risk patients. This test is performed using the EsoCheck® Esophageal Cell Collection Device, which allows for a brief and noninvasive office procedure, aiming to enhance cancer prevention efforts and reduce the incidence of cancer-related deaths through widespread screening initiatives.

In addition to its participation in the upcoming forum, Lucid Diagnostics has issued a forward-looking statement highlighting potential risks and uncertainties that may impact the company’s performance. These include stock price volatility, economic conditions, challenges in research and development, and regulatory approvals. Furthermore, the ongoing effects of the COVID-19 pandemic on business operations remain a concern. Lucid continues to monitor these variables closely as it seeks to advance its mission in cancer prevention and improve patient outcomes.

Lucid’s commitment to innovating in the cancer diagnostics space is not only pivotal for patient health but also reflects broader trends in the medical technology industry. As companies increasingly prioritize early detection and preventative measures, Lucid’s participation in key industry events underscores its role in shaping the future of cancer diagnostics. For more details about their initiatives and offerings, interested parties can visit the company's website at www.luciddx.com or PAVmed’s website at www.pavmed.com.